The FDA’s announcement this summer that it would take enforcement action against several unapproved formulations of ear drops provides a great opportunity for a pharmaceutical company that would like to develop an NDA for this type of product.
Unapproved prescription products containing the following ingredients are affected by this action:
Of course, FDA's action does not impact approved prescription products or legally marketed over-the-counter (OTC) products.
It is likely that the 505(b)(2) path could be followed for one of these compounds. Since these therapies have been available for decades it is possible that safety and efficacy could be demonstrated based on available relevant literature, thereby minimizing or eliminating the necessity of conducting clinical trials.
The Weinberg Group has assisted a number of clients in obtaining literature-based NDA approvals. The typical process is:
If you need assistance in developing an NDA for one of these ear drop formulations, or any other compound, please contact us.
May 18, 2022
The FDA’s Office of Clinical Pharmacology within the Office of Translational Sciences released a new draft guidance document that, for the first time, clearly addresses the FDA’s recommendations and...
April 27, 2022
GUIDANCE DOCUMENT April 2022 This guidance is one in a series of guidance documents intended to assist industry when making certain regulatory submissions in electronic format to FDA’s Center for...
June 27, 2022
On June 23, 2022, The FDA issued the final version of its Guidance for Industry titled “Assessing the Effects of Food on Drugs in INDs and NDAs - Clinical Pharmacology Considerations”. The most...